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Edited by Horst FeldmannAbstract Lewy bodies (LBs) are the pathologic hallmark of
Parkinson’s disease. Recent studies revealed that LBs exhibit
several morphologic and molecular similarities to aggresomes.
Aggresomes are perinuclear aggregates representing intracellu-
lar deposits of misfolded proteins. Recently, valosin-containing
protein (VCP) was one of the components of LBs, suggesting
its involvement in LB formation. Here, we showed the localiza-
tion of VCP in aggresomes induced by a proteasome inhibitor
in cultured cells. Cells overexpressing mutant VCP (K524M:
D2) showed reduced aggresome formation relative to those over-
expressing wild-type and mutant (K251M: D1) VCPs. Our ﬁnd-
ings suggest that the D2 domain is involved in aggresome
formation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinson’s disease (PD) is characterized histopathologically
by the relatively selective loss of dopaminergic neurons in the
substantia nigra and the presence of Lewy bodies (LBs) [1]. Re-
cent studies suggest that LBs are related to aggresomes [2]. The
latter are formed upon exhaustion of neuronal cell machinery
responsible for the degradation of misfolded proteins [3]. Fur-
thermore, aggresomes are formed at the microtubule (MT)-
organizing center (MTOC) and are deﬁned as pericentriolar
membrane-free cytoplasmic inclusions that contain misfolded,
ubiquitinated proteins ensheathed in a cage of the intermediate
ﬁlament (IF) protein, vimentin [3,4].
Valosin-containing protein (VCP) is a 97-kDa protein and a
member of type II ATPases associated with a variety of cellu-
lar activities (AAA), which are characterized by the presence of
two conserved ATPase domains, also called AAA domains [5].
Recent studies revealed that VCP acts as a molecular chaper-
one in many apparently unrelated cellular activities [6]. Among
these activities, VCP recognizes misfolded proteins such as*Corresponding author. Fax: +81 3 3813 7440/5800 0547.
E-mail address: nhattori@med.juntendo.ac.jp (N. Hattori).
0014-5793/$32.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.12.044polyglutamine [7]. Indeed, VCP is recognized in nuclear inclu-
sion bodies of polyglutamine diseases [8]. Moreover, VCP is
also recognized in LBs of PD [8,9].
Based on the above background, we postulated that VCP is
involved in the formation of aggresomes. To test this, we
examined the induction of VCP in aggresomes of cells treated
with a proteasome inhibitor, MG132, and the role of VCP in
aggresome formation.2. Materials and methods
2.1. Plasmids and antibodies
We constructed pUHD10-3/VCPWT-Myc, pCMV/FLAG-6c-
VCPWT, and pCMV/FLAG-6c-VCPK251M/K524M for this experiment.
pUHD10-3/VCPWT-Myc was digested and inserted into the XhoI site
of the pcDNA3.1 vector (Invitrogen). pcDNA3.1/FLAG-VCPWT was
prepared by polymerase chain reaction (PCR) using appropriately
designed primers with restriction site (BamHI). The PCR product
was inserted into the pcDNA3.1 vector. pcDNA3.1/FLAG-VCPK251M,
FLAG-VCPK524M were prepared by using QuikChange Site-Directed
Mutagenesis Kit (Stratagene). These point mutants lack two ATPases
activity domains such as D1 and D2 [8]. pcDNA3.1/a-synucleinWT and
pcDNA3.1/FLAG-IjBaWT were kind gifts from Drs. Suzuki and Chi-
ba (The Tokyo Metropolitan Institute of Medical Science, Tokyo). We
prepared FLAG-tagged a-synuclein to examine the interaction
between VCP and a-synuclein.
The following antibodies were used in the present study; anti-VCP
polyclonal antibody (Santa Cruz), anti-ubiquitin monoclonal antibody
(Chemicon), anti-FLAG polyclonal antibody (Aﬃniti), anti-FLAG-
HRP (Aﬃniti), anti-Myc monoclonal antibody (Santa Cruz), anti-
vimentin monoclonal antibody (Sigma), anti-b actin monoclonal
antibody (Sigma), anti-c-tubulin monoclonal antibody (Sigma), and
anti-Hsp70 antibody (BD Transduction Laboratories).
2.2. Cell culture and transfection
Kidney cell lines, HEK293 cells were grown in Dulbeccos modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 lg/ml streptomycin. Conﬂuent cells were
transfected with 9 lg Myc-vector, VCPWT-Myc, 5 lg FLAG-a-synuc-
lein and 2 lg FLAG-IjBa. At 24 h after transfection, the cells were
lysed with 500 ll lysis buﬀer (150 mM NaCl, 50 mM Tris–HCl [pH
7.5], 1.0% nonidet-P40, 10% glycerol, 1 M dithiothreitol) and protease
inhibitor cocktail; Complete Mini. The lysate was then centrifuged at
17000 · g for 15 min at 4 C, and then 30 ll volume of the supernatant
was used as the ‘‘lysate’’ for SDS–PAGE, while 450 ll volume of the
supernatant was used for immunoprecipitation. For immunoprecipita-
tion, 2 lg anti-Myc antibody was added to each 450 ll of the superna-
tant and the mixture was rotated for 3 h at 4 C, then centrifuged at
17000 · g for 15 min. The supernatants were mixed with 20 ll protein
G-Sepharose (Amersham Biosciences), rotated for 3 h at 4 C, thenblished by Elsevier B.V. All rights reserved.
Fig. 1. Subcellular localization of endogenous VCP and ubiquitin in
SH-SY5Y cells treated or untreated with a proteasome inhibitor. SH-
SY5Y cells were treated with 10 lM MG132 (A) or DMSO (B) for
24 h. Cells were stained with anti-VCP and anti-ubiquitin antibodies
Nuclei were stained with DAPI (blue). FITC (green) and Alexa (red)
correspond to VCP and ubiquitin, respectively. After treatment with
MG132, both VCP and ubiquitin showed perinuclear accumulation
and colocalization and appeared as clear protein aggregates (arrows)
Nuclear torsion was observed (arrowhead). Scale bar = 20 lm.
M.-I. Kitami et al. / FEBS Letters 580 (2006) 474–478 475centrifuged at 1800 · g for 5 min, washed three times and then mixed
with 30 ll of the sample buﬀer. The samples were separated by
SDS–PAGE (10–20% gradient gel) and transferred onto a PVDF
membrane. Finally, detection was performed with anti-FLAG-HRP
antibody (1:2000) and anti-Myc monoclonal antibody (1:2000).
2.3. Cell culture and immunological analysis
SH-SY5Y neuroblastoma cell and HEK 293 cells were grown in
DMEM containing 10% FBS, 100 U/ml penicillin and 100 lg/ml strep-
tomycin. Conﬂuent cells were treated with 10 lM MG132 (Sigma),
proteasome inhibitor and dimethyl sulfoxide (DMSO; Sigma) (for con-
trol) for 0, 4, or 8 h. The cells were lysed with lysis buﬀer (150 mM
NaCl, 50 mM Tris–HCl [pH 7.5], 1.0% nonidet-P40, 10% glycerol
and cocktail: Complete Mini; Roche). The lysate was then centrifuged
at 17000 · g for 15 min at 4 C. Next, the supernatant was used as the
‘‘crude’’. We considered the presence of aggregation in the pellet frac-
tion and accordingly the pellet was solubilized with a mixture of 6 M
urea, 50 mM Tris–HCl [pH 7.5], and 5 mM 2-mercaptoethanol, and
sonicated. We then added the sample buﬀer to the sonicated sample
as the ‘‘pellet’’. The whole lysates were prepared using the same meth-
od. The samples were separated by SDS–PAGE and transferred onto a
PVDF membrane. Finally, detection was performed with VCP poly-
clonal and ubiquitin monoclonal antibodies.
2.4. Immunohistochemistry
After growing on 35-mm dishes (with glass coverslips), SH-SY5Y or
HEK293 cells were treated with 10 lM MG132 or DMSO for 24 h.
The cells were ﬁxed in 4% paraformaldehyde in PBS for 30 min and
permealized with Triton-X 100 for 20 min. Then, the cells were blocked
overnight at 4 C with 4% normal goat serum in PBS, incubated over-
night with anti-VCP and anti-ubiquitin, anti-vimentin, anti-c-tubulin,
anti-Hsp70, and anti-FLAG antibodies in each case, washed with
0.01% Triton-X 100, and incubated for 30 min with Alexa 543 nm
anti-mouse antibody and FITC 488 nm anti-rabbit antibody. The cov-
erslips were washed and mounted on one vectashield. Fluorescence
images were obtained using a ﬂuorescence microscope.
2.5. Cell viability
HEK293 cells were grown under the same conditions. Conﬂuent
cells were transfected with 5 lg of FLAG-vector, FLAG-VCPWT,
FLAG-VCPK251M, FLAG-VCPK524M, or FLAG-VCPK251M/K524M.
The next day, the cells were transferred to 96-well dishes. After 1 h,
the cells were treated with 10 lM MG132 or DMSO, and the cell via-
bility was analyzed the next day. We used the MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay kit
(Dojindo). We repeated the same experiments four times. To conﬁrm
the eﬃciencies of expression level, transfected cells were lysed with lysis
buﬀer and centrifuged. We then added the sample buﬀer to the super-
natant samples and applied them on the SDS–PAGE. In addition, we
performed Western blotting with anti-FLAG, anti-VCP and anti-b-ac-
tin antibodies.3. Results and discussion
Recent studies showed that cells treated with MG132 form
aggregates that resemble LBs [10]. We ﬁrst investigated
whether VCP exists in such aggregates. As shown in Fig. 1,
VCP was found in an aggregate formed under MG132. We
also found that VCP levels were increased in the insoluble frac-
tion, similar to polyubiquitinated proteins under MG132 con-
dition, but not DMSO (Fig. 2). This ﬁnding indicates that
these aggresomes were detergent insoluble and that VCP and
ubiquitinated proteins were components of this fraction. Un-
der this condition, the supernatant VCP fraction did not de-
crease at the same time, suggesting upregulation of VCP in
the detergent-insoluble fraction. On the other hand, no in-
crease in the whole VCP fraction was detected, suggesting that
the amounts of supernatant fractions were larger than the
insoluble fractions..
.In the next step, we investigated the localization of endoge-
nous VCP in aggresomes. VCP formed a single large perinu-
clear aggresome-like structure and was co-localized with
ubiquitin. Nuclear torsion was also noted (Fig. 1). Then we
characterized the structure of these aggresomes to determine
whether it is similar to that of typical aggresomes [3]. As shown
in Fig. 3A, VCP-positive aggresomes were surrounded by
vimentin in MG132-treated cells. Aggregates of misfolded pro-
teins that escape degradation are targeted and accumulate in
the MTOC. Subsequently, aggresomes are formed in the
MTOC [3]. First, we showed that VCP-positive aggresomes
co-localized with c-tubulin, a marker of MTOC (Fig. 3B). Sec-
ond, aggresomes are also abundant in chaperones such as
Hsp70 [11]. We observed that Hsp70 co-localized with VCP
in such aggresomes (Fig. 3C). Finally, we investigated the ef-
fect of inhibition of microtubule dynamics using an anti-mito-
tic agent, nocodazole, on the formation of these aggresomes.
Co-incubation of cells with 10 lM nocodazole and MG132 re-
sulted in inhibition of aggresome formation as evident in VCP
and vimentin staining (Fig. 3D). These results indicate that the
VCP-positive aggregates in SH-SY5Y cells are typical aggre-
somes.
We next examined the involvement of VCP in aggresome
formation. We prepared FLAG-vector, FLAG-VCPWT,
FLAG-VCPK251M, FLAG-VCPK524M, and FLAG-
VCPK251M/K524M. The latter three vectors encode proteins
lacking the function of two ATPase domains, D1 and D2,
respectively. Considering the transfection eﬃciency, we used
Fig. 2. Endogenous VCP moved to insoluble fraction similar to
polyubiquitin under treatment with proteasome inhibitor. Cells were
treated with 10 lM MG132 and DMSO for 0, 4 and 8 h. While VCP
was identiﬁed in the supernatant fraction (A), it moved to the insoluble
fraction (A) similar to polyubiquitin in MG132-treated cells (B).
Fig. 3. VCP-positive aggregates are aggresomes. SH-SY5Y cells were
treated with 10 lMMG132 or DMSO for 24 h, then stained with anti-
VCP (A–D), anti-vimentin (A, D), anti-c-tubulin (B) or anti-Hsp70
antibodies (C). Nuclei were stained with DAPI (blue). FITC (green)
represents VCP and Alexa (red) represents vimentin (A, D), c-tubulin
(B) or Hsp70 (C). In MG132-treated cells, VCP-positive aggregates are
surrounded by vimentin (A). Co-localization studies with anti-VCP
and c-tubulin antibodies showed VCP-positive aggresomes co-local-
ized with c-tubulin in MG132-treated cells (B). Hsp70 also co-localized
with VCP-positive aggresomes (C). Inhibition of microtubule dynam-
ics by antimitotic agent, nocodazole, was associated with inhibition of
VCP and vimentin staining in MG132-treated cells (D; nocodazole and
MG132). Scale bar = 20 lm.
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mechanisms of aggresome formation have been well studied
in HEK293 cell lines [3]. The proportions of aggresomes-con-
taining FLAG-VCPK524M- and FLAG-VCPK251M/K524M-
transfected HEK293 cells were signiﬁcantly lower than others
(Fig. 4A). However, there was no signiﬁcant diﬀerence in cell
viability among FLAG-VCPK524M-, FLAG-VCPK251M/K524M-
transfected HEK293 cells and cells transfected with other plas-
mids before treatment with MG132, as FLAG-VCPK524M and
FLAG-VCPK251M/K524M mutants tended to induce cell loss. In
contrast, treatment with MG132 signiﬁcantly inﬂuenced the
viability of cells overexpressing FLAG-VCPK524M, FLAG-
VCPK251M/K524M, and others. Considering the enhancement ef-
fects of MG132, we calculated the ratio of cell viability under
DMSO and MG132, e.g., the ratio of FLAG-VCPWT/FLAG-
vector (under MG132) and FLAG-VCPWT/FLAG-vector (un-
der DMSO). There was no signiﬁcant diﬀerence among the
transfected cells. Thus, cell death of HEK293 cells with diﬀer-
ent expression vectors was similar under MG132 (Fig. 4B).
Furthermore, the expression levels of exogenous FLAG-vec-
tors were almost equal, suggesting that the transfection eﬃ-
ciencies of the vectors are similar. Indeed, the ratios of
endogenous VCP to transfected FLAG-VCPs were almost
1:1 (Fig. 4C). These results suggest that the D2 domain of
VCP is required for the formation of aggresomes rather than
for cell death. Hirabayashi et al. [8] reported that cell viability
was signiﬁcantly reduced in mutant D2 VCP-transfected cells.
In the previous report, the increased ratio of transfected mu-
tant D2 VCP to wild-type VCP was inversely associated with
cell viability. The discrepancy may be due to the diﬀerent
expression level of mutant VCP.As reported previously [8,9], VCP is localized in LBs of PD
patients. Thus, it is possible that VCP interacts with a-synuc-
lein within LBs. However, wild-type VCP did not interact with
a-synuclein while IjBa as a positive control interacted with
Fig. 4. Overexpression of VCPs aﬀects aggresome formation. (A)
HEK293 cells were transfected with FLAG-vector, FLAG-VCPWT,
FLAG-VCPK251M, FLAG-VCPK524M, or FLAG-VCPK251M/K524M
vectors. The cells were then treated with MG132 after 24 h and
harvested at 48 h after transfection. Anti-FLAG antibody and anti-
vimentin antibody were used for detection of aggresome-containing
transfected cells. Data are mean ± S.D. of the proportion of aggre-
some-containing cells. *P < 0.005, **P < 0.01, by Student’s paired
t-test. (B) Cell viability was analyzed using MTT assay. There was no
signiﬁcant diﬀerence among the ratios of each overexpression FLAG-
VCPWT, FLAG-VCPK251M, FLAG-VCPK524M, and FLAG-
VCPK251M/K524M cells. (I = FLAG-VCPWT, FLAG-VCPK251M,
FLAG-VCPK524M, or FLAG-VCPK251M/K524M/FLAG-vector [under
MG132 treatment]), II = FLAG-VCPWT, FLAG-VCPK251M, FLAG-
VCPK524M, or FLAG-VCPK251M/K524M/FLAG-vector [under DMSO
treatment]. (C) Wild-type and mutant FLAG-VCPs and FLAG-vector
were only expressed in HEK293 cells. Immunoblotting was performed
with anti-FLAG, anti-VCP and anti-b-actin antibodies. The ratio of
endogenous VCP to transfected FLAG-VCPs was 1:1.
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suggest that VCP and a-synuclein do not interact directly with
each other.
VCP consists of two ATP binding sites: D1, which exhibits
a heat-enhanced ATPase activity, and D2, which exhibits
ATPase activity. D1 is responsible for the formation of sta-
ble hexamers while D2 has a major ATPase activity
[6,13,14]. The ATPase activity of VCP is modulated by var-
ious environmental factors, similar to molecular chaperones.
In the present study, fewer cells with aggresomes were noted
among the cells transfected with D2 mutant VCP. In con-
trast, the proportion of aggresomes-containing cells was not
signiﬁcantly diﬀerent between wild-type VCP- and mock-
transfected cells, suggesting that endogenous VCP is involved
in aggresome formation. Therefore, the D2 mutant VCP re-
duced the frequency of aggresomes as a dominant negative
eﬀect. On one hand, the lack of increment in wild-type
VCP suggests that there is some rate-control process in
aggresome formation. For example, dynein motor proteincontributes to aggresome formation, and this step is thought
to be a physically a rate-controlling step [3,15,16]. The dom-
inant negative eﬀect may be related to the inhibition of the
nuclear-to-cytosol translation of VCP under MG132 treat-
ment.
A recent study concluded that aggresome is important in LB
formation [10], based on three reasons. The ﬁrst is that LB
consists of various proteins involved in the ubiquitin-protea-
some system such as ubiquitinated proteins, proteasome sub-
units, parkin, a-synuclein, synphillin-1, Hsp70, and Hsp40
[11,17–19]. The second is the perinuclear localization, which
is similar to LBs [2,10]. The third is the morphological similar-
ity in the halo and core structures of LBs. The ﬁnding that
VCP contributes to aggresome formation may enhance our
understanding of the biogenesis of LBs.References
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